You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
DiaSorin said that the acquisition gives it access to Luminex's multiplexing technology, tests, and instruments and strengthens its MDx product portfolio.
Core revenues were up 10 percent organically, while COVID-19 testing contributed $535 million to revenues in Q1 2021.
The researchers found that the reliable sampling of rare circulating tumor DNA fragments served as the key challenge for developing liquid biopsy assays.
Four newly published PCR variant assays could potentially help health officials surveil communities and triage patients.
The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.
In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.
The company aims to enroll up to 2,000 people and use its Serum Epitope Repertoire Analysis technology to assess their immune responses over five years.
The multi-center study is evaluating the use of Cofactor's OncoPrism test in predicting head and neck cancer patients' response to immunotherapy with other tumor types to follow.
Ethos said Agena's MALDI-TOF-based MassArray system will allow for more rapid and lower-cost detection of SARS-Cov-2 variants than next-generation sequencing.
A study showed that chromothripsis, a mutational process that can lead to congenital disease and cancer, can result from on-target editing with Cas9.
CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.
According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.